CELADON PHARMACEUTICALS PLC

Regulatory Filings • Mar 29, 2022

National Storage Mechanism | Additional information

RNS Number : 3693G

Celadon Pharmaceuticals PLC

29 March 2022

29 March 2022

Celadon Pharmaceuticals Plc

("Celadon" or the "Company") 

Change of name

Further to yesterday's announcement, the Company confirms that, the change of name from Summerway Capital plc to Celadon Pharmaceuticals Plc, is effective on the London Stock Exchange as of today.

As a result, the Company's stock market ticker is now CEL and its ISIN and SEDOL remain unchanged. The change of name will not affect any rights of shareholders and existing share certificates should be retained as they will remain valid and no new share certificates will be issued.

Enquiries:

Celadon Pharmaceuticals Plc
Mo Noonan	078 764 44977
Canaccord Genuity Limited (Nominated Adviser and Broker)
Andrew Potts / Patrick Dolaghan	020 7523 800

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company targeting the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. Its UK facility comprises a laboratory designed to meet UK-GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK. 

For further information please visit our website www.celadonpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CANSEMSMUEESEID